Glaxo
May 16, 2012 at 14:42 | Source: Moneycontrol.com
May 07, 2012 at 18:00 | Source: Moneycontrol.com
May 07, 2012 at 15:19 | Source: Moneycontrol.com
May 07, 2012 at 14:27 | Source: Moneycontrol.com
May 07, 2012 at 08:05 | Source: CNBC-TV18
News across the web »
May 28, 2012 at 02:31 | Source: Business Standard
May 25, 2012 at 16:22 | Source: Market Watch
May 25, 2012 at 03:11 | Source: Forbes
May 24, 2012 at 06:00 | Source: Business Week
May 22, 2012 at 22:11 | Source: The Hindu BusinessLine
Interact & exchange stock tips & market info »
Related News »
GlaxoSmithKline Plc (GSK) will reveal detailed results today on an experimental treatment for diabetes that’s part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc. (HGSI), its partner on the drug. Glaxo will ...
May 24, 2012 at 22:38 | Source: Bloomberg
The deal provides Glaxo with exclusive rights to co-promote Testim in the U.S. with Auxilium Pharma through September 30, 2015. Glaxo will use its established sales force to promote Testim to testosterone replacement therapy (TRT) prescribers, especially ...
May 22, 2012 at 14:05 | Source: Zacks.com
LONDON — GlaxoSmithKline may find its next acquisition target where it found the last two: among more than a dozen companies it collaborates with to develop new treatments. Glaxo has stakes in more than 10 publicly traded companies, including DiaDexus ...
May 24, 2012 at 15:29 | Source: nola.com
British pharma giant GlaxoSmithKline (GSK) recently announced that it has completed the acquisition of 10,000,000 shares of biopharmaceutical company Theravance Inc. (THRX). Shares were acquired for approximately $21.2887 per share. Theravance ...
May 17, 2012 at 16:42 | Source: Yahoo Finance
GlaxoSmithKline (GSK - Analyst Report) recently announced that it has entered into an agreement to acquire 80.02% shares of a U.K. and Germany-based, privately-owned company, Cellzome, for a cash payment of £61 million (U.S. $99 million). Glaxo already ...
May 16, 2012 at 14:41 | Source: Zacks.com
GlaxoSmithKline (NYSE: GSK) has moved into Phase III studies for its melanoma drug cocktail treatment. The trial evaluates the combination of dabrafenib, and trametinib- a BRAF inhibitor and an MEK inhibitor, respectively. BRAF is a human gene ...
May 29, 2012 at 14:40 | Source: The Business Journal
MALVERN, Pa. (AP) -- Drug developer Auxilium Pharmaceuticals Inc. improved its outlook for 2012 because of plans to start co-promoting its testosterone gel Testim in the U.S. this summer with British pharmaceutical giant GlaxoSmithKline plc.
May 29, 2012 at 01:18 | Source: Yahoo Finance
The lawsuit asserts that the company’s board of directors did not uphold its financial responsibilities when it rejected a $2.6 billion proposal from Glaxo last month. Additionally, the filing claims that actions taken by the company’s board ...
May 29, 2012 at 15:09 | Source: Washington Post
(Reuters) - Human Genome Sciences Inc said on Thursday it had adopted a stockholder rights plan as the biotechnology company defends itself against a $2.6 billion hostile takeover bid by drugmaker GlaxoSmithKline Plc. Human Genome said its board ...
May 17, 2012 at 12:02 | Source: msnbc.com
Human Genome Sciences (HGSI) has adopted a stockholder rights plan - known widely as a “poison pill” defense strategy - in an effort to protect itself from a hostile takeover bid by rival drug maker GlaxoSmithKline (GSK). The biotechnology ...
May 17, 2012 at 13:57 | Source: FOXBusiness